Immunotherapy in Translational Cancer Research
Cancer Vaccines for Solid Tumors
Publication
, Chapter
Vreeland, TJ; Herbert, GS; Peoples, GE
April 13, 2018
Since the late 19th century, when William Coley first injected cancer patients with "Coley's Toxin," we have been searching for a method of inoculation that will effectively harness the power of the immune system to destroy cancer cells. In the realm of solid tumors, multiple vaccines have been developed with this goal in mind. These vaccines conform to one of five strategies: dendritic cell vaccines, tumor cell vaccines, protein-based vaccines, viral vaccines, or an anti-idiotypic antibody vaccine. In this chapter, we comprehensively describe the successes of each of these strategies, focusing on vaccines that have made it to phase III trials.
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Vreeland, T. J., Herbert, G. S., & Peoples, G. E. (2018). Cancer Vaccines for Solid Tumors. In Immunotherapy in Translational Cancer Research (pp. 72–90). https://doi.org/10.1002/9781118684535.ch6
Vreeland, T. J., G. S. Herbert, and G. E. Peoples. “Cancer Vaccines for Solid Tumors.” In Immunotherapy in Translational Cancer Research, 72–90, 2018. https://doi.org/10.1002/9781118684535.ch6.
Vreeland TJ, Herbert GS, Peoples GE. Cancer Vaccines for Solid Tumors. In: Immunotherapy in Translational Cancer Research. 2018. p. 72–90.
Vreeland, T. J., et al. “Cancer Vaccines for Solid Tumors.” Immunotherapy in Translational Cancer Research, 2018, pp. 72–90. Scopus, doi:10.1002/9781118684535.ch6.
Vreeland TJ, Herbert GS, Peoples GE. Cancer Vaccines for Solid Tumors. Immunotherapy in Translational Cancer Research. 2018. p. 72–90.